Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy A Brighton

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Research and Practice in Thrombosis and Haemostasis|May 1, 2023
Platelet-activating functional assay resolution in vaccine-induced immune thrombotic thrombocytopenia: differential alignment to PF4 ELISA platformsChristine S M Lee, Lisa J Clarke, Geoffrey W Kershaw, et al.
Thrombosis Journal|September 24, 2013
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studiesMartin H Prins, Anthonie Wa Lensing, Rupert Bauersachs, et al.
Blood|December 24, 2015
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy useIda Martinelli, Anthonie W A Lensing, Saskia Middeldorp, et al.
Chest|June 6, 2016
Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-ExtensionPhilip S Wells, Martin H Prins, Bennett Levitan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2019
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple MyelomaTimothy A Brighton, Amit Khot, Simon J Harrison, et al.
Thrombosis and Haemostasis|May 22, 2015
Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE studyJeffrey I Weitz, Rupert Bauersachs, Jan Beyer-Westendorf, et al.
BMJ Open|September 24, 2017
Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysisFaizan Khan, Alvi Rahman, Marc Carrier, et al.
Blood Advances|April 11, 2018
Risk of recurrent venous thromboembolism according to baseline risk factor profilesMartin H Prins, Anthonie W A Lensing, Paolo Prandoni, et al.
The New England Journal of Medicine|March 21, 2017
Rivaroxaban or Aspirin for Extended Treatment of Venous ThromboembolismJeffrey I Weitz, Anthonie W A Lensing, Martin H Prins, et al.
BMJ (Clinical Research Ed.)|July 26, 2019
Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysisFaizan Khan, Alvi Rahman, Marc Carrier, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Research and Practice in Thrombosis and Haemostasis|May 1, 2023
Platelet-activating functional assay resolution in vaccine-induced immune thrombotic thrombocytopenia: differential alignment to PF4 ELISA platformsChristine S M Lee, Lisa J Clarke, Geoffrey W Kershaw, et al.
Thrombosis Journal|September 24, 2013
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studiesMartin H Prins, Anthonie Wa Lensing, Rupert Bauersachs, et al.
Blood|December 24, 2015
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy useIda Martinelli, Anthonie W A Lensing, Saskia Middeldorp, et al.
Chest|June 6, 2016
Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-ExtensionPhilip S Wells, Martin H Prins, Bennett Levitan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2019
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple MyelomaTimothy A Brighton, Amit Khot, Simon J Harrison, et al.
Thrombosis and Haemostasis|May 22, 2015
Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE studyJeffrey I Weitz, Rupert Bauersachs, Jan Beyer-Westendorf, et al.
BMJ Open|September 24, 2017
Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysisFaizan Khan, Alvi Rahman, Marc Carrier, et al.
Blood Advances|April 11, 2018
Risk of recurrent venous thromboembolism according to baseline risk factor profilesMartin H Prins, Anthonie W A Lensing, Paolo Prandoni, et al.
The New England Journal of Medicine|March 21, 2017
Rivaroxaban or Aspirin for Extended Treatment of Venous ThromboembolismJeffrey I Weitz, Anthonie W A Lensing, Martin H Prins, et al.
BMJ (Clinical Research Ed.)|July 26, 2019
Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysisFaizan Khan, Alvi Rahman, Marc Carrier, et al.
Pageof 3